A Phase IV Double-Blind Placebo-Controlled Multi-Center Trial To Study The Effects Of Evolocumab In Stage IV-V Chronic Kidney Disease: The Cardiovascular and Lipid-Lowering Effects Of Evolocumab In Advanced Chronic Kidney Disease Trial (EVO-CKD)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Chronic Kidney Disease
  • Age: Between 40 - 80 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Participants diagnosed with CKD Stage 4-5
    2. Low-density lipoprotein (LDL) =70 mg/dL and Treatment with maximal tolerated doses of a statin OR Statin intolerance defined as any history of intolerance or allergy to =1 statin
    3. Participants =60 years old are required to have =1 of the following cardiovascular risk factors:
      • History of CV disease
      • History of peripheral vascular disease
      • Diabetes
      • Smoking
      • Baseline LDL =160 mg/dL
      • Macroalbuminuria (albumin to creatinine ratio =300 mg/g on spot sample)

You may not be eligible for this study if the following are true:

    1. Participants who are expected survival less than 1 year
    2. Participants who are expected a transplant within 1 year
    3. Active liver disease
    4. Malignancy within 5 years
    5. Currently enrolled in another interventional study
    6. Female subject who has not used at least (1) effective method of birth control for at least 1 month prior to screening or (2) is not willing to use such a method during treatment and for an additional 15 weeks after the end of treatment
    7. Pregnant or breast-feeding participants
    8. Known sensitivity or intolerance to study medications



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.